Zacks Investment Research upgraded Ritter Pharmaceuticals Inc (NASDAQ:RTTR) to Hold in a report released today.
- Updated: September 20, 2016
Zacks Investment Research has upgraded Ritter Pharmaceuticals Inc(NASDAQ:RTTR) to Hold in a report released on 9/20/2016.
Showing a price of $1.43, Ritter Pharmaceuticals Inc (NASDAQ:RTTR) traded 2.89% higher on the day. With the last stock price close down 2.83% from the two hundred day moving average, compared with the S&P 500 which has fallen -0.01% over the same time period. The company has logged a 50-day moving average of $1.34 and two hundred day average of $1.49. 35,755 shares of the stock were exchanged, down from ann avg. trading volume of 58,323
Ritter Pharmaceuticals Inc has a one-year low of $0.98 and a 52 week high of $3.17 . Ritter Pharmaceuticals Inc’s total market value is presently $0.0.
A total of 2 brokerages have reported on the company. Zero rate the company a strong buy, two analysts rate the company a buy, 0 firms rate the stock a hold, 0 rate the company to underperform, and lastly 0 brokeragesrate the company as sell with an average target stock price of $5.00
More About Ritter Pharmaceuticals Inc (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, and an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.